Functional deletion mutation of the 5'-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese.

The natriuretic peptide (NP) family is involved in the regulation of blood pressure and fluid volume. We isolated the 5'-flanking region of the type A human NP receptor gene and identified an insertion/deletion mutation in this region. We then assessed whether there is a genetic association between this mutation and essential hypertension (EH). The deletion allele lacks 8 nucleotides and alters binding sites for the activator protein-2 (AP-2) and Zeste transcriptional factors. We genotyped 200 EH and 200 normotensive (NT) individuals and found 9 subjects with the deletion (8 in the EH group and 1 in the NT group). All 9 individuals were heterozygous. The NT subject with the mutation had left ventricular hypertrophy without hypertension. Transcriptional activity of the deletion allele was <30% that of the wild-type allele. The plasma levels of brain NP in EH patients with the deleted allele were significantly higher than the levels in the EH patients with the wild-type allele, and plasma brain NP levels were significantly higher in subjects with the deleted allele than in subjects with the wild-type allele, despite comparable blood pressures. These findings suggest that in Japanese individuals, this deletion in the human NP receptor gene reduces receptor activity and may confer increased susceptibility to developing EH or left ventricular hypertrophy.

[1]  T. Nakayama,et al.  Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension. , 1999, Circulation research.

[2]  T. Nakayama,et al.  Organization of the human natriuretic peptide receptor A gene. , 1998, Biochemical and biophysical research communications.

[3]  H. S. Kim,et al.  Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  T. Nakayama,et al.  Nonsense mutation of prostacyclin synthase gene in a family , 1997, The Lancet.

[5]  K. Bailey,et al.  Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. , 1996, Hypertension.

[6]  S. Antonarakis,et al.  Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2. , 1996, Genomics.

[7]  T. Ishimitsu,et al.  Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. , 1996, Hypertension.

[8]  D. Clemmons,et al.  Transcription Factor AP-2 Regulates Human Insulin-like Growth Factor Binding Protein-5 Gene Expression (*) , 1995, The Journal of Biological Chemistry.

[9]  K. Nakao,et al.  Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. , 1995, The Journal of clinical investigation.

[10]  Yaoguang Liu,et al.  Thermal asymmetric interlaced PCR: automatable amplification and sequencing of insert end fragments from P1 and YAC clones for chromosome walking. , 1995, Genomics.

[11]  N. Tamura,et al.  Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. , 1994, The Journal of clinical investigation.

[12]  R. Glockshuber,et al.  An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2 , 1993, Molecular and cellular biology.

[13]  D. Bonthron,et al.  Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Moorman,et al.  Identification and functional characterization of regulatory elements of the glutamine synthetase gene from rat liver. , 1993, European journal of biochemistry.

[15]  Steven C. Hunt,et al.  Molecular basis of human hypertension: Role of angiotensinogen , 1992, Cell.

[16]  J. R. Jewett,et al.  Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. , 1991, The Journal of biological chemistry.

[17]  H. Imura,et al.  Hemodynamic, Renal, and Hormonal Responses to Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure , 1991, Circulation.

[18]  D. Goeddel,et al.  Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). , 1991, Science.

[19]  D. Garbers,et al.  The primary structure of the rat guanylyl cyclase A/atrial natriuretic peptide receptor gene. , 1990, The Journal of biological chemistry.

[20]  T. Mohandas,et al.  Chromosomal distribution of three members of the human natriuretic peptide receptor/guanylyl cyclase gene family. , 1990, Genomics.

[21]  L. Field,et al.  Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. , 1990, Hypertension.

[22]  K. Nakao,et al.  Human brain natriuretic peptide, a novel cardiac hormone , 1990, The Lancet.

[23]  E. Chen,et al.  Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases , 1989, Nature.

[24]  D. Goeddel,et al.  Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. , 1989, The EMBO journal.

[25]  H. Itoh,et al.  Brain natriuretic peptide is a novel cardiac hormone. , 1989, Biochemical and biophysical research communications.

[26]  S. Meloche,et al.  Atrial natriuretic factor R1 receptor from bovine adrenal zona glomerulosa: purification, characterization, and modulation by amiloride. , 1988, Biochemistry.

[27]  J. Lewicki,et al.  Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. , 1988, The Journal of biological chemistry.

[28]  H. Imura,et al.  Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. , 1987, Circulation.

[29]  J. Lewicki,et al.  Purification and subunit composition of atrial natriuretic peptide receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Nakao,et al.  PLASMA CONCENTRATION OF ATRIAL NATRIURETIC POLYPEPTIDE IN ESSENTIAL HYPERTENSION , 1985, The Lancet.

[31]  J. Laragh,et al.  Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis. , 1985, The New England journal of medicine.

[32]  Mark G. Currie,et al.  Atriopeptins as cardiac hormones. , 1985, Hypertension.

[33]  J. Laragh,et al.  Atrial natriuretic factor: structure and functional properties. , 1985, Kidney international.

[34]  N. Martell,et al.  Volume overload, atrial natriuretic peptide, and left ventricular hypertrophy. , 1997, Advances in experimental medicine and biology.

[35]  D. Garbers,et al.  Guanylyl cyclase-linked receptors. , 1992, Annual review of neuroscience.